Contrasting Oxford Immunotec Global (OXFD) and Trinity Biotech (TRIB)

Oxford Immunotec Global (NASDAQ: OXFD) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Institutional & Insider Ownership

How to Become a New Pot Stock Millionaire

93.3% of Oxford Immunotec Global shares are owned by institutional investors. Comparatively, 62.1% of Trinity Biotech shares are owned by institutional investors. 8.1% of Oxford Immunotec Global shares are owned by company insiders. Comparatively, 12.7% of Trinity Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Oxford Immunotec Global and Trinity Biotech, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Immunotec Global 0 0 4 0 3.00
Trinity Biotech 0 0 0 0 N/A

Oxford Immunotec Global currently has a consensus target price of $18.75, indicating a potential upside of 43.13%. Given Oxford Immunotec Global’s higher probable upside, research analysts clearly believe Oxford Immunotec Global is more favorable than Trinity Biotech.

Volatility and Risk

Oxford Immunotec Global has a beta of -0.32, suggesting that its stock price is 132% less volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Earnings & Valuation

This table compares Oxford Immunotec Global and Trinity Biotech’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oxford Immunotec Global $103.08 million 3.29 -$32.88 million ($1.36) -9.63
Trinity Biotech $99.14 million 1.23 $2.30 million $0.26 19.54

Trinity Biotech has lower revenue, but higher earnings than Oxford Immunotec Global. Oxford Immunotec Global is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Oxford Immunotec Global and Trinity Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oxford Immunotec Global -31.90% -42.38% -23.65%
Trinity Biotech -40.62% 2.37% 0.99%

Summary

Trinity Biotech beats Oxford Immunotec Global on 7 of the 13 factors compared between the two stocks.

About Oxford Immunotec Global

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.

About Trinity Biotech

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech’s blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

ColossusCoinXT 1-Day Trading Volume Reaches $91,527.00
ColossusCoinXT 1-Day Trading Volume Reaches $91,527.00
QuinStreet Inc  Director Sells $2,513,114.92 in Stock
QuinStreet Inc Director Sells $2,513,114.92 in Stock
UnitedHealth Group’s  “Buy” Rating Reaffirmed at Piper Jaffray
UnitedHealth Group’s “Buy” Rating Reaffirmed at Piper Jaffray
Halliburton  PT Raised to $51.00 at Bank of America
Halliburton PT Raised to $51.00 at Bank of America
Insider Selling: Nektar Therapeutics  SVP Sells 13,881 Shares of Stock
Insider Selling: Nektar Therapeutics SVP Sells 13,881 Shares of Stock
Continental Resources  Downgraded to “Hold” at Zacks Investment Research
Continental Resources Downgraded to “Hold” at Zacks Investment Research


Leave a Reply

© 2006-2018 Ticker Report. Google+.